Melanoma sentinel node biopsy and prediction models for relapse and overall survival

British Journal of Cancer

Volumn 103, Issue 8, 2010, Pages 1229-1236

  Mitra, A ^a   Conway, C ^a   Walker, C ^b   Cook, M ^b   Powell, B ^c   Lobo, S ^a   Chan, M ^a   Kissin, M ^b   Layer, G ^b   Smallwood, J ^d   Ottensmeier, C ^d   Stanley, P ^e   Peach, H ^f   Chong, H ^c   Elliott, F ^a   Iles, M M ^a   Nsengimana, J ^a   Barrett, J H ^a   Bishop, D T ^a   Newton Bishop, J A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^e HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^f LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

formalin fixed tissue; melanoma; osteopontin; prognosis; sentinel node biopsy

Indexed keywords

OSTEOPONTIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER RELAPSE; CLINICAL FEATURE; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MITOSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; ADOLESCENT; AGED; CHILD; CLINICAL TRIAL; EVALUATION STUDY; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SKIN NEOPLASMS; SURVIVAL; THEORETICAL MODEL; VALIDATION STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MELANOMA; MIDDLE AGED; MODELS, THEORETICAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77957999561     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605849     Document Type: Article

References (43)

1. Balch CM, Sober AJ, Soong SJ, Gershenwald JE (2003) The new melanoma staging system. Semin Cutan Med Surg 22: 42-54
2. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A (2001) Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: 3622-3634
3. Clark Jr WH, Elder DE, Guerry Dt, Braitman LE, Trock BJ, Schultz D, Synnestvedt M, Halpern AC (1989) Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81: 1893-1904
4. Cochran AJ, Elashoff D, Morton DL, Elashoff R (2000) Individualized prognosis for melanoma patients. Hum Pathol 31: 327-331
5. Conway C, Mitra A, Jewell R, Randerson-Moor J, Lobo S, Nsengimana J, Edward S, Sanders DS, Cook M, Powell B, Boon A, Elliott F, de Kort F, Knowles MA, Bishop DT, Newton-Bishop J (2009) Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res 15: 6939-6946
6. Cook MG, Green MA, Anderson B, Eggermont AM, Ruiter DJ, Spatz A, Kissin MW, Powell BW (2003) The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol 200: 314-319
7. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS (2006) The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 17: 463-474
8. Elder D, Murphy G (1991) Malignant tumours (melanoma and related lesions). Vol. 2. Atlas of Tumor Pathology: Melanocytic Tumours of the Skin. Armed Forces Institute of Pathology: Washington
9. Ferrone CR, Panageas KS, Busam K, Brady MS, Coit DG (2002) Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol 9: 637-645
10. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, Lee JJ, Balch CM, Reintgen DS, Ross MI (1999) Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17: 976-983
11. Gutzmer R, Satzger I, Thoms KM, Volker B, Mitteldorf C, Kapp A, Bertsch HP, Kretschmer L (2008) Sentinel lymph node status is the most important prognostic factor for thick (X4 mm) melanomas. J Dtsch Dermatol Ges 6: 198-203
12. Hsieh YH, Juliana MM, Hicks PH, Feng G, Elmets C, Liaw L, Chang PL (2006) Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontin. Cancer Res 66: 7119-7127
13. Illumina (2005a) DASL Assay vs. Direct Hybridization. Technology Spotlight Pub.No.470-2005-001
14. Illumina (2005b) RNA Profiling with the DASL Assay. Technical Bulletin Pub.No. 470-2005-003
15. Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, Kunz M (2007)Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 13: 806-815
16. Johnson Jr OK, Emrich LJ, Karakousis CP, Rao U, Greco WR (1985) Comparison of prognostic factors for survival and recurrence in malignant melanoma of the skin, clinical Stage I. Cancer 55: 1107-1117
17. Kashani-Sabet M, Venna S, Nosrati M, Rangel J, Sucker A, Egberts F, Baehner FL, Simko J, Leong SP, Haqq C, Hauschild A, Schadendorf D, Miller III JR, Sagebiel RW (2009) A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res 15: 6987-6992
18. Kauffmann A, Rosselli F, Lazar V, Winnepenninckx V, Mansuet-Lupo A, Dessen P, van den Oord JJ, Spatz A, Sarasin A (2008) High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 27: 565-573
19. Kesmodel SB, Karakousis GC, Botbyl JD, Canter RJ, Lewis RT, Wahl PM, Terhune KP, Alavi A, Elder DE, Ming ME, Guerry D, Gimotty PA, Fraker DL, Czerniecki BJ, Spitz FR (2005) Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 12: 449-458
20. Kruper LL, Spitz FR, Czerniecki BJ, Fraker DL, Blackwood-Chirchir A, Ming ME, Elder DE, Elenitsas R, Guerry D, Gimotty PA (2006) Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer 107: 2436-2445
21. Lens MB, Dawes M, Newton-Bishop JA, Goodacre T (2002) Tumour thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsy. Br J Surg 89: 1223-1227
22. McMasters KM, Wong SL, Edwards MJ, Ross MI, Chao C, Noyes RD, Viar V, Cerrito PB, Reintgen DS (2001) Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery 130: 151-156
23. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Glass EC, Wang HJ (2006) Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355: 1307-1317
24. Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, Miller III JR, Leong SP (1998) Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. Arch Dermatol 134: 983-987
25. Nguyen CL, McClay EF, Cole DJ, O'Brien PH, Gillanders WE, Metcalf JS, Maize JC, Baron PL (2001) Melanoma thickness and histology predict sentinel lymph node status. Am J Surg 181: 8-11
26. Paek SC, Griffith KA, Johnson TM, Sondak VK, Wong SL, Chang AE, Cimmino VM, Lowe L, Bradford CR, Rees RS, Sabel MS (2007) The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer 109: 100-108
27. Philip S, Bulbule A, Kundu GC (2001) Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factorkappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 276: 44926-44935
28. Pinero A, Canteras M, Ortiz E, Martinez-Barba E, Parrilla P (2008) Validation of a nomogram to predict the presence of sentinel lymph node metastases in melanoma. Ann Surg Oncol 15: 2874-2877
29. Porter GA, Ross MI, Berman RS, Lee JE, Mansfield PF, Gershenwald JE (2000) Significance of multiple nodal basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. Ann Surg Oncol 7: 256-261
30. Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16: 79-87
31. Rangel J, Nosrati M, Torabian S, Shaikh L, Leong SP, Haqq C, Miller III JR, Sagebiel RW, Kashani-Sabet M (2008) Osteopontin as a molecular prognostic marker for melanoma. Cancer 112: 144-150
32. Rittling SR, Chambers AF (2004) Role of osteopontin in tumour progression. Br J Cancer 90: 1877-1881
33. Rousseau DL, Ross MI, Johnson MM, Prieto VG, Lee JE, Mansfield PF, Gershenwald JE (2003) Revised american joint committee on cancer staging criteria accurately predict sentinel lymph node positivity in clinically node negative melanoma patients. Ann Surg Oncol 10: 569-574
34. Sartore L, Papanikolaou GE, Biancari F, Mazzoleni F (2008) Prognostic factors of cutaneous melanoma in relation to metastasis at the sentinel lymph node: a case-controlled study. Int J Surg 6: 205-209
35. Sondak VK, Taylor JM, Sabel MS, Wang Y, Lowe L, Grover AC, Chang AE, Yahanda AM, Moon J, Johnson TM (2004) Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 11: 247-258
36. Taylor RC, Patel A, Panageas K, Busam K, Brady MS (2007) Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 7: 869-875
37. Team RDC (2010) R: A language and environment for statistical computing. R Foundation for statistical computing
38. Wagner JD, Gordon MS, Chuang TY, Coleman III JJ, Hayes JT, Jung SH, Love C (2000) Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 89: 453-462
39. Wang KX, Denhardt DT (2008) Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 19: 333-345
40. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98: 472-482
41. Wong SL, Kattan MW, McMasters KM, Coit DG (2005) A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann Surg Oncol 12: 282-288
42. Workman C, Jensen LJ, Jarmer H, Berka R, Gautier L, Nielser HB, Saxild HH, Nielsen C, Brunak S, Knudsen S (2002) A new non-linear normalization method for reducing variability in DNA microarray experiments. Genome Biol 3: research0048
43. Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, Campos EI, Dorocicz I, Tang L, Huntsman D, Nelson C, Ho V, Li G (2005) Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 124: 1044-1052